CN103857413A - 载体连接的曲罗尼尔前药 - Google Patents

载体连接的曲罗尼尔前药 Download PDF

Info

Publication number
CN103857413A
CN103857413A CN201280049725.9A CN201280049725A CN103857413A CN 103857413 A CN103857413 A CN 103857413A CN 201280049725 A CN201280049725 A CN 201280049725A CN 103857413 A CN103857413 A CN 103857413A
Authority
CN
China
Prior art keywords
carrier
alkyl
formula
linked
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049725.9A
Other languages
English (en)
Chinese (zh)
Inventor
U·赫泽尔
H·拉乌
T·莱斯曼
N·比塞科
G·迈特罗
K·斯普罗格
T·韦格
O·凯尔
J·策特勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of CN103857413A publication Critical patent/CN103857413A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280049725.9A 2011-08-12 2012-08-10 载体连接的曲罗尼尔前药 Pending CN103857413A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11177409.7 2011-08-12
EP11177409 2011-08-12
EP11195615 2011-12-23
EP11195615.7 2011-12-23
EP12165508.8 2012-04-25
EP12165508 2012-04-25
PCT/EP2012/065745 WO2013024052A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Publications (1)

Publication Number Publication Date
CN103857413A true CN103857413A (zh) 2014-06-11

Family

ID=46690494

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049725.9A Pending CN103857413A (zh) 2011-08-12 2012-08-10 载体连接的曲罗尼尔前药

Country Status (14)

Country Link
US (2) US9561287B2 (2)
EP (1) EP2741781A1 (2)
JP (1) JP6092867B2 (2)
KR (1) KR101997939B1 (2)
CN (1) CN103857413A (2)
AU (1) AU2012296954B2 (2)
BR (1) BR112014003225A2 (2)
CA (1) CA2843883C (2)
HK (1) HK1198359A1 (2)
IL (1) IL230712A (2)
IN (1) IN2014CN00989A (2)
MX (1) MX349950B (2)
WO (1) WO2013024052A1 (2)
ZA (1) ZA201400977B (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349926A (zh) * 2015-06-17 2018-07-31 康赛制药公司 曲前列环素衍生物及其组合物和用途
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CN116113415A (zh) * 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
WO2023131349A1 (zh) * 2022-01-07 2023-07-13 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349950B (es) * 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
CA2868925C (en) * 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
EP2928501B1 (en) 2012-12-07 2020-05-06 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
JP6263604B2 (ja) * 2013-03-25 2018-01-17 ユナイテッド セラピューティクス コーポレイション チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
ES2908142T3 (es) * 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
JP6561109B2 (ja) * 2014-07-16 2019-08-14 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
CA2967899C (en) * 2014-12-03 2023-09-19 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
MY208384A (en) 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
RU2757903C2 (ru) 2016-09-15 2021-10-22 Камурус Аб Препараты аналогов простациклина
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
KR102627405B1 (ko) 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
CN112334152A (zh) 2018-05-18 2021-02-05 阿森迪斯药物骨疾病股份有限公司 Pth缀合物的起始剂量
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
AU2020204785A1 (en) 2019-01-04 2021-06-03 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
PH12021551591A1 (en) 2019-01-04 2022-04-18 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
EP3906065B1 (en) 2019-01-04 2025-04-30 Ascendis Pharma Oncology Division A/S Prr agonist for use in the treatment of cancer
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
AU2020295725A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Anti-CTLA4 conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
TW202114660A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 酪胺酸激酶抑制劑結合物
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
MX2022007371A (es) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.
EP4146281A1 (en) 2020-05-04 2023-03-15 Ascendis Pharma A/S Hydrogel irradiation
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
WO2022194195A1 (zh) * 2021-03-16 2022-09-22 江苏恒瑞医药股份有限公司 一种曲前列环素衍生物及其用途
IL311539A (en) 2021-09-22 2024-05-01 Ascendis Pharma Bone Diseases As Long-acting pth compound treatments
MX2024006698A (es) 2021-12-13 2024-06-19 Ascendis Pharma Oncology Div A/S Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
IL326658A (en) 2023-09-04 2026-04-01 Ascendis Pharma Bone Diseases As PTH treatment in chronic kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354622A (zh) * 1999-03-31 2002-06-19 联合治疗公司 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
ATE441418T1 (de) * 2003-12-16 2009-09-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
JP2010518122A (ja) 2007-02-09 2010-05-27 ユナイテッド セラピューティクス コーポレーション 間質性肺疾患および喘息のためのトレプロスチニル処置
SI2173890T1 (sl) * 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
AU2009282413B2 (en) * 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP2485767A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
MX349950B (es) * 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354622A (zh) * 1999-03-31 2002-06-19 联合治疗公司 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349926A (zh) * 2015-06-17 2018-07-31 康赛制药公司 曲前列环素衍生物及其组合物和用途
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11802105B2 (en) 2015-06-17 2023-10-31 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11866402B2 (en) 2015-06-17 2024-01-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CN116113415A (zh) * 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
WO2023131349A1 (zh) * 2022-01-07 2023-07-13 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途

Also Published As

Publication number Publication date
JP6092867B2 (ja) 2017-03-08
IN2014CN00989A (2) 2015-04-10
CA2843883C (en) 2020-04-28
US20140296150A1 (en) 2014-10-02
KR20140070545A (ko) 2014-06-10
HK1198359A1 (en) 2015-04-10
IL230712A0 (en) 2014-03-31
BR112014003225A2 (pt) 2017-03-01
EP2741781A1 (en) 2014-06-18
MX2014001497A (es) 2014-04-25
AU2012296954A1 (en) 2014-02-20
US9561287B2 (en) 2017-02-07
WO2013024052A1 (en) 2013-02-21
US20190105400A1 (en) 2019-04-11
AU2012296954B2 (en) 2016-09-15
MX349950B (es) 2017-08-22
CA2843883A1 (en) 2013-02-21
JP2014527050A (ja) 2014-10-09
IL230712A (en) 2017-08-31
US10729778B2 (en) 2020-08-04
ZA201400977B (en) 2017-11-29
KR101997939B1 (ko) 2019-07-08

Similar Documents

Publication Publication Date Title
CN103857413A (zh) 载体连接的曲罗尼尔前药
CN103874480A (zh) 前列环素的缓释组合物
JP6710253B2 (ja) Ａｐｊ受容体アゴニストおよびその使用
JP6290243B2 (ja) 担体連結プロスタノイドプロドラッグ
ES2959995T3 (es) Pauta de dosificación para un compuesto de pth de liberación controlada
CA2708819C (en) An erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
AU2024259730A1 (en) IL-2 conjugates
JP2021138761A (ja) 四級化チューブリシン化合物の複合体
ES3012647T3 (en) Controlled-release pth compounds
CN107405409A (zh) Cnp前药
WO2021213492A1 (zh) 一类载药的大分子及其制备方法
HK1197731A (en) Carrier-linked treprostinil prodrugs
US8642555B2 (en) Prodrugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197731

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140611

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1197731

Country of ref document: HK